

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Cancel Claims 1-18.

19. (New) A method of providing pain relief to a patient comprising administering to said patient an effective amount of a compound of formula I:



wherein R represents C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl or C₂₋₂₀ alkynyl; and n is an integer from 0 to 3.

20. (New) The method of claim 19 further comprising administering one or more analgesics to the patient.
21. (New) The method of claim 19 wherein, in the compound of formula I, R represent C₁₀₋₂₀ alkyl, C₁₀₋₂₀ alkenyl, or C₁₀₋₂₀ alkynyl.
22. (New) The method of claim 19 wherein, in the compound of formula I, R represents C₁₀₋₂₀ *n*-alkyl, C₁₀₋₂₀ mono-alkenyl or C₁₀₋₂₀ mono-alkynyl.
23. (New) The method of claim 19 wherein, in the compound of formula I, R represents C₁₀₋₂₀ *n*-alkyl, C₁₀₋₂₀ mono-*n*-alkenyl or C₁₀₋₂₀ mono-*n*-alkynyl.
24. (New) The method of claim 19 wherein, in the compound of formula I, R represents C₁₁₋₁₉ *n*-alkyl, or C₁₁₋₁₉ mono-*n*-alkenyl.
25. (New) The method of claim 19 wherein, in the compound of formula I, R represents C₁₁₋₁₈ *n*-alkyl, or C₁₁₋₁₈ mono-*n*-alkenyl.
26. (New) The method of claim 19 wherein, in the compound of formula I, the alkenyl or alkynyl groups have no more than 3 C-C double or triple bonds, respectively.

27. (New) The method of claim 19 wherein, in the compound of formula I, *n* represents 0 or 1.
28. (New) The method of claim 19 wherein, in the compound of formula I, *n* represents 1.
29. (New) The method of claim 19 wherein the compound is *N*-(2-propenyl) hexadecanamide, *N*-(2-propenyl) cis-9-octadecenamide, *N*-(2-propenyl) cis-9-hexadecenamide, *N*-(2-propenyl) tetradecanamide, *N*-(2-propenyl) cis-9-tetradecenamide, *N*-(2-propenyl) octadecanamide, *N*-(2-propenyl) trans-9-octadecenamide, *N*-(2-propenyl) dodecanamide, or *N*-(2-propenyl) cis-5-dodecenamide.
30. (New) The method of claim 29 wherein the compound is *N*-(2-propenyl) hexadecanamide.
31. (New) The method of claim 31, wherein the compound is not *N*-(2-propenyl) – 5,8,11,14-eicosatetraenamide.
32. (New) The method of claim 20, wherein the analgesic is an opioid, a non-steroidal anti-inflammatory drug, a local anaesthetic, a NMDA receptor antagonist, a cannabinoid, an antidepressant, and/or an anticonvulsant.
33. (New) A pharmaceutical composition comprising a compound as defined in claim 19 and one or more analgesics and a pharmaceutically acceptable excipient.
34. (New) The pharmaceutical composition of claim 33, wherein the compound is *N*-(2-propenyl) hexadecanamide, *N*-(2-propenyl) cis-9-octadecenamide, *N*-(2-propenyl) cis-9-hexadecenamide, *N*-(2-propenyl) tetradecanamide, *N*-(2-propenyl) cis-9-tetradecenamide, *N*-(2-propenyl) octadecanamide, *N*-(2-propenyl) trans-9-octadecenamide, *N*-(2-propenyl) dodecanamide, or *N*-(2-propenyl) cis-5-dodecenamide.
35. (New) The pharmaceutical composition of claim 33, wherein the analgesic is an opioid, a non-steroidal anti-inflammatory drug, a local anaesthetic, a NMDA receptor antagonist, a cannabinoid, an antidepressant, and/or an anticonvulsant.

36. (New) A kit of parts comprising:
- (a) a compound as defined in claim 19; and,
 - (b) one or more analgesics; and,
 - (c) a pharmaceutically acceptable excipient.
37. (New) The kit of claim 36, wherein the compound is N-(2-propenyl) hexadecanamide, N-(2-propenyl) cis-9-octadecenamide, N-(2-propenyl) cis-9-hexadecenamide, N-(2-propenyl) tetradecanamide, N-(2-propenyl) cis-9-tetradecenamide, N-(2-propenyl) octadecanamide, N-(2-propenyl) trans-9-octadecenamide, N-(2-propenyl) dodecanamide, or N-(2-propenyl) cis-5-dodecenamide.
38. (New) The kit of claim 37, wherein the analgesic is an opioid, a non-steroidal anti-inflammatory drug, a local anaesthetic, a NMDA receptor antagonist, a cannabinoid, an antidepressant, and/or an anticonvulsant.